India-based Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines. The company enjoys a strong position in the generics market.
Currently, Dr. Reddy’s has a Zacks Rank #4 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Dr. Reddy’s third quarter fiscal 2019 earnings of 41 cents per share, compared with 29 cents reported in the year ago quarter.
Revenues Beat: Dr. Reddy’s posted revenues of $553 million an increase of 1.1% year over year.
Key Statistics:Revenues from Global Gereics segment increased 4% year over year, and from the Pharmaceutical Services and Active Ingredients (PSAI) segment increased 9% year over year. Sales from the Proprietary Products segment declined 66% from the year ago quarter.
Pre-Market Trading: Shares increased 2.6% in pre-market trading.
Check back later for our full write up on this RDY earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
India-based Dr. Reddy’s Laboratories Ltd. (RDY - Free Report) is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines. The company enjoys a strong position in the generics market.
Currently, Dr. Reddy’s has a Zacks Rank #4 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Dr. Reddy’s third quarter fiscal 2019 earnings of 41 cents per share, compared with 29 cents reported in the year ago quarter.
Revenues Beat: Dr. Reddy’s posted revenues of $553 million an increase of 1.1% year over year.
Key Statistics:Revenues from Global Gereics segment increased 4% year over year, and from the Pharmaceutical Services and Active Ingredients (PSAI) segment increased 9% year over year. Sales from the Proprietary Products segment declined 66% from the year ago quarter.
Pre-Market Trading: Shares increased 2.6% in pre-market trading.
Check back later for our full write up on this RDY earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on RDY - FREE